FRAT2 antibody (AA 131-230) (Cy7)

Catalog No. ABIN1708429

Product Details anti-FRAT2 Antibody (Cy7)

Target: FRAT2 (Frequently Rearranged in Advanced T-Cell Lymphomas 2 (FRAT2))

Binding Specificity: AA 131-230

Reactivity: Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This FRAT2 antibody is conjugated to Cy7

Application: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Cross-Reactivity: Mouse

Predicted Reactivity: Human,Rat,Dog,Cow,Sheep

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human FRAT2

Isotype: IgG

Application Details

Application Notes: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details for FRAT2

Target: FRAT2 (Frequently Rearranged in Advanced T-Cell Lymphomas 2 (FRAT2))

Alternative Name: FRAT2 (FRAT2 Products)

Synonyms: FRAT2 antibody, FRAT2, WNT signaling pathway regulator antibody, frequently rearranged in advanced T cell lymphomas 2 antibody, frequently rearranged in advanced T-cell lymphomas 2 antibody, FRAT2 antibody, Frat2 antibody

Background:

Synonyms: Frequently rearranged in advanced T-cell lymphomas 2 antibodyGSK-3 binding protein FRAT2, FRAT2_HUMAN.

Background: FRAT1 and FRAT2 were originally characterized as proteins frequently rearranged in advanced T cell lymphoma, and they have since been identified as proto-oncogenes involved in tumorigenesis. These proteins share significant homology with the Xenopus glycogen synthase kinase-3 (xGSK-3) binding protein, which is designated GBP and is essential for the formation of the dorsal-ventral axis during embryonic development. Establishment of these embryonic axes is mediated by the Wnt intracellular signaling pathway. Wnt signaling is regulated in part by the activity of GSK-3, which phosphorylates and thereby facilitates the degradation of ?catenin. GBP binds to GSK-3 and inhibits this phosphorylation, resulting in the accumulation of ?catenin and the subsequent transcription of Wnt target genes. Like GBP, FRAT2 has been shown to bind xGSK-3, suggesting that FRAT1 and FRAT2 may be GSK-3 regulatory proteins.

Gene ID: 23401